A086820 Stock Overview
Develops, manufactures, and sells cell therapy products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Bio Solution Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩17,500.00 |
| 52 Week High | ₩24,050.00 |
| 52 Week Low | ₩11,710.00 |
| Beta | 0 |
| 11 Month Change | 2.88% |
| 3 Month Change | 16.90% |
| 1 Year Change | 17.45% |
| 33 Year Change | -17.65% |
| 5 Year Change | -46.15% |
| Change since IPO | -38.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| A086820 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 7.5% | -1.5% | 0.9% |
| 1Y | 17.4% | 23.1% | -3.4% |
Return vs Industry: A086820 underperformed the KR Biotechs industry which returned 23.1% over the past year.
Return vs Market: A086820 exceeded the KR Market which returned -3.4% over the past year.
Price Volatility
| A086820 volatility | |
|---|---|
| A086820 Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A086820 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A086820's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | n/a | www.biosolutions.co.kr |
Bio Solution Co.,Ltd. develops, manufactures, and sells cell therapy products worldwide. The company offers CartiLife, an autologous chondrocyte cell-based therapy for the restoration of symptomatic and structural complications caused by articular cartilage defects; KeraHeal-Allo, a thermosensitive hydrogel-type allogenic keratinocyte cell-therapy product to promote re-epithelialization of deep 2nd-degree burn wounds; and KeraHeal, an autologous spray-type keratinocyte cell-based therapy for skin wounds.
Bio Solution Co.,Ltd. Fundamentals Summary
| A086820 fundamental statistics | |
|---|---|
| Market cap | ₩139.13b |
| Earnings (TTM) | -₩1.28b |
| Revenue (TTM) | ₩8.27b |
0.0x
P/S Ratio0.0x
P/E RatioIs A086820 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A086820 income statement (TTM) | |
|---|---|
| Revenue | ₩8.27b |
| Cost of Revenue | ₩3.57b |
| Gross Profit | ₩4.70b |
| Other Expenses | ₩5.98b |
| Earnings | -₩1.28b |
Last Reported Earnings
Mar 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A086820 perform over the long term?
See historical performance and comparison